7. April 2016: Julian Hitchcock spoke at the Royal Society of Medicine

Julian spoke at the Royal Society of Medicine on the impact of the General Data Protection Regulation and other impending EU regulations on medical and healthcare apps and related digital healthcare systems.

8. February 2016: Julian Hitchcock wrote an article for BioNews entitled ‘The distracting genome’

In an article published in BioNews (here), Julian discusses the regulation of embryonic gene editing in the UK following the HFEA's decision to extend the Francis Crick Institute's research licence to include studies involving CRISPR/Cas9 embryonic gene editing.

4. February 2016: Julian Hitchcock spoke at Informa’s Genome Editing Applications Conference

Julian spoke on regulatory strategies for translating genome editing and CRISPR therapeutics into the clinic at Informa's Genome Editing Applications Conference in Brussels.

26. January 2016: Julian Hitchcock spoke at the University of Cambridge’s inter-disciplinary workshop

Julian spoke at the University of Cambridge's inter-disciplinary workshop on gene editing at Jesus College, Cambridge. The meeting was organised by the University's Public Policy Strategic Initiative in association with the Welcome Trust - Medical Research Council Cambridge Stem Cell Institute.

20. January 2016: Julian Hitchcock spoke at the Festival of Genomics in London

Julian spoke on human embryonic gene editing in research at the Festival of Genomics in London. The discussion was organised by the Progress Educational Trust.

12. January 2016: Launch of the textbook 'Stem Cells in Regenerative Medicine'

Denoon Legal congratulates Alain Vertes, Nasib Quershi, Arnold Caplan and Lee Babiss on the launch of the comprehensive textbook 'Stem Cells in Regenerative Medicine' published by Wiley Blakewell (here).

Alex Denoon and Julian Hitchcock of Denoon Legal were proud to contribute a chapter regarding the European regulatory and IP landscape together with James Lawford Davies.

15. September 2015: Julian Hitchcock appointed as a Trustee at Science Media Centre (“SMC”)

We are very pleased to announce that Julian has been appointed as a Trustee at the Science Media Centre (“SMC”). The SMC is an independent venture working to promote the voices, stories and views of the scientific community to the national news media when science is in the headlines. 

14. September 2015: Alex Denoon attended a meeting organised by the European Alliance for Personalised Medicine

Alex attended a meeting in Brussels organised by the European Alliance for Personalised Medicine. This was the "kick off" meeting of the Health Data Access & Accountability Task Force. Attendees included representatives from patient organisations, clinicians and researchers; pharmaceutical companies; software and hardware companies and representatives from European Commission.

9. September 2015: Alex Denoon participated in the ABPI Legal Day at the RSM on 9 September 2015

Alex co-presented on managing a disaster scenario with Dominic Hornblow from Astra Zeneca and Aileen Thompson from the ABPI.

7. September 2015: Julian Hitchcock spoke on the impact of regulation on innovation policy at @MEIbioeng15

On 7 September, Julian spoke on the impact of regulation on innovation policy at @MEIbioeng15, the UK’s largest gathering of biomedical engineers, bioengineers and medical engineers. The event was organised by the Royal Academy of Engineering and the University of Leeds.

10. July 2015: Julian Hitchcock is giving a series of one-to-one life science clinics at the Judge Business School of the University of Cambridge

Julian helped to found the life science stream of the University's international enterprise course, Ignite, in 2010. Details may be found here.

1. July 2015: We're pleased to announce the launch of Denoon Legal, the exclusive life sciences law firm.

We will continue to focus solely on Life Sciences, working with our colleagues and friends in the Alliance of European Life Sciences Law Firms, to continue to deliver specialist advice to life sciences leaders in this dynamic sector. Clients demand specialist advice to manage the fast-moving legal, regulatory and policy landscape in Europe and the UK.

James Lawford Davies has joined Hempsons, a leading UK healthcare practice. We wish James well in his new role.

Denoon Legal Limited is the same legal entity as Lawford Davies Denoon Limited and maintains the same registration details and service offering.

10. February 2015: Alex Denoon presented at the Clinical Operations & Outsourcing Medical Device Trials Conference in Munich on 10 – 11 February 2015

Alex spoke at the Clinical Operations & Outsourcing Medical Device Trials Conference in Munich on 11 February 2015. Alex gave a presentation on the ‘Ramifications of the changes to data protection framework on clinical investigations’.

29. January 2015: Alex Denoon presented at the IMCAS Annual World Congress 2015 Conference in Paris

Alex spoke at the IMCAS Annual World Congress 2015 Conference in Paris on 29 January 2015. Alex gave a presentation on the ‘Regulation of Stem Cell Therapies in UK’.

18. December 2014: LDD was cited in Nature’s report of the decision by the Court of Justice of the European Union in International Stem Cell Corporation v Comptroller General of Patents, Designs and Trade Marks

Today, the Court of Justice of the European Union (“CJEU”) gave its judgment in the important stem cell patent case, International Stem Cell Corporation v Comptroller General of Patents, Designs and Trade Marks. Nature’s report of the decision, which concerned the patentability of human parthenotes in Europe, reported remarks by LDD’s Julian Hitchcock about serious evidential flaws in the landmark Brüstle case of 2011. 

21. November 2014: Julian Hitchcock will be giving a lecture at Hughes Hall, University of Cambridge on 28 November 2014

Julian is giving a lecture on "Inflammatory property: the ambiguous relationship between life sciences and intellectual property" at Hughes Hall, University of Cambridge on 28 November 2014.

20. November 2014: Julian Hitchcock spoke at a joint meeting of the Academy of Medical Sciences and the Royal Academy of Engineering

Julian gave a presentation on the law and regulation of health apps at a joint meeting of the Academy of Medical Sciences and the Royal Academy of Engineering in London on 18 November 2014.

6. October 2014: Lawford Davies Denoon recommended by Legal 500 in Pharmaceuticals and Biotechnology


Lawford Davies Denoon is delighted to be recognised as ‘a niche life sciences firm’ with ‘specialist regulatory and litigation capabilities, in areas such as medical devices, cell therapies and IVF law’ in the latest (2014) edition of the Legal 500. Alex Denoon is commended for delivering ‘out-of-the-box solutions'. Julian Hitchcock recognised as ‘commercially astute with technical insight’. Please see here for the full review.

23. July 2014: Julian Hitchcock was guest blogger for this week's Managing Intellectual Property


Julian Hitchcock, as guest blogger for this week's Managing Intellectual Property, writes on the potential impact of the International Stem Cell patent case in the Court of Justice of the European Union (here).

22. July 2014: UK Government's Review of the Competences between the United Kingdom and the European Union: Fundamental Rights


Evidence from Lawford Davies Denoon, in connection with the life science sector, figured in the UK Government's Review of the Competences between the United Kingdom and the European Union: Fundamental Rights, published on 22 July 2014 (here).

21. May 2014: Julian Hitchcock spoke at the Entrepreneurship: Emerging Technologies (ETECH Projects) Programme


Julian spoke at the Entrepreneurship: Emerging Technologies (ETECH Projects) Programme, hosted by the Judge Business School, University of Cambridge, on 21 May 2014. Julian presented a lecture on intellectual property exploitation to MPhil and MBA students (Emerging Technologies Projects).

14. April 2014: Wellcome Trust stands up for EU funded research


LDD is supporting the Wellcome Trust, which has lead a group of 31 research organisations across Europe in a statement opposing radical legislative proposals contained in the “One of Us” citizens’ initiative, the effect of which would be to block EU funding for research involving the use of surplus IVF embryos and to threaten implementation of the fifth UN Millenium Development Goal which seeks to ensure universal access to reproductive health. Interviewed by Science magazine, Julian Hitchcock said that the Brüstle patent case, upon which the campaigners rest their case, does not declare the point at which human life and dignity begins.

7. April 2014: European Society of Human Genetics today publishes a legal Opinion by LDD and Axon


European Society of Human Genetics
today publishes a legal Opinion by LDD and Axon, challenging the legitimacy of controversial amendments to the proposed IVD Regulation.

20. March 2014: Alex Denoon co-chaired a session on ‘Intellectual Property: The Legal view’

Alex co-chaired a session on ‘Intellectual Property: The Legal view’at the 17th International Conference on Pharmaceutical Medicine and 30th DGPharMed Annual Meeting in Berlin on 20th March 2014.

13. March 2014: HFEA decide not to appeal against Beth Warren

We are very pleased that the HFEA have decided not to appeal against last week's High Court judgment. The HFEA issued a press release here which states that they "have concluded that the likelihood of future problems is not strong enough to warrant appealing in this case". Beth is now free to use the stored samples in accordance with the Court's declaration and we wish her all the very best for the future.

6. March 2014: Victory for Beth Warren

We are delighted that the High Court today confirmed that Beth's application for a declaration allowing her late husband's sperm to remain in storage has been successful. A copy of the judgment is available here and the judge's summary is here.  

19. February 2014: Alex presented at the Clinical Operations & Outsourcing Medical Device Trials 2014 Conference in Frankfurt on 19 February 2014

Alex Denoon presented at a conference (Clinical Operations & Outsourcing Medical Device Trials 2014) in Frankfurt on 19 February 2014. Alex's lecture related to the changing regulatory framework (for medical devices, in-vitro diagnostics, data protection and clinical trials).

31. January 2014: Alex attended a workshop considering Strategies for Responsible Sharing of Clinical Trial Data

Alex Denoon was invited to attend a workshop hosted by The Wellcome Trust on 31 January 2014 considering Strategies for Responsible Sharing of Clinical Trial Data. The workshop was based on a Study by the US Institute of Medicine. The workshop discussed the challenges with establishing systems for sharing clinical data. Based on his practical experience, Alex was able to comment on technical and legal issues (with a focus on the changing regulatory landscape).

4. December 2013: LDD acting for Beth Warren

LDD is acting for Elizabeth Warren in relation to her application to the High Court for a declaration that it would be lawful for her late husband's sperm to remain in storage. Further information is set out in this press release.

3. December 2013: ARGC and RGI v HFEA success

LDD acted for the Assisted Reproduction and Gynaecology Centre and the Reproductive Genetics Institute in their successful judicial review of the Human Fertilisation and Embryology Authority's decision to vary the clinics' licences before the completion of a statutory appeals process. Mrs Justice Patterson said that "In my judgment the defendant has no power to impose a condition which takes effect on a licence prior to completion of the full statutory process up to and including the appeal process provided for in section 20 of the 1990 Act" and further that "...the conduct of the defendant towards the claimants has not been fair. A fair outcome would have been to have retained the status quo until the end of the appeals process". The clinics were awarded their costs and a copy of the full judgment is available here.

26. September 2013: Alex Denoon invited to speak at a Lunch Debate on Data protection and Health/Medical Research

Alex Denoon was invited to speak on 26 September 2013 at a Lunch Debate on Data protection and Health/Medical Research, hosted by MEP Marielle Gallo and organised by EURORDIS and EPIRARE. This is an important issue for biomedical research and particularly for the development of therapies and diagnostics for rare diseases. Alex was pleased to have an opportunity to explain the perspective of those developing such therapies and diagnostics to such a distinguished audience, include the acting shadow rapporteur for data protection Baroness Ludford MEP.

20. September 2013: Alex Denoon attends Cell Therapy Society meeting in San Diego to discuss the regulatory framework for cell-based therapies

Alex Denoon was pleased to attend Cell Society's annual clinical meeting in San Diego on 20 September 2013 to participate in a lively panel discussion regarding the regulatory framework for cell-based therapies in multiple jurisdictions.

2. July 2013: LDD invited to contribute to inquiry into Regenerative Medicine conducted by the House of Lords Select Committee

LDD was very pleased to have been invited to contribute to the important and wide reaching inquiry into Regenerative Medicine conducted by the House of Lords Select Committee on Science and Technology. The report may be found here.

13. May 2013: Julian Hitchcock to speak at the first public forum of the Emerging Science & Bioethics Advisory Committee at the Department of Health

Julian Hitchcock will be speaking on innovative governance at the first public forum of the Emerging Science & Bioethics Advisory Committee at the Department of Health on 13 May 2013.

26. April 2013: Alex Denoon conducting post-conference workshop with Mathias Klümper and Erik Vollebregt

Alex conducted a post-conference workshop with Mathias Klümper and Erik Vollebregt re Practical Advice on Successful Software, Electronic Data Capture and Apps for Clinical Evaluations and Investigations at the Clinical Evaluations and Investigations for Medical Devices Conference in Dublin on 26 April 2013.

26. April 2013: LDD submitted observations to the European Patent Office regarding Brüstle stem cell patent

LDD submitted observations to the European Patent Office in connection with opposition proceedings concerning the patenting of inventions derived from human fertilised eggs.

12. February 2013: Lawford Davies Denoon advises on $305 million deal

Lawford Davies Denoon advised the owners in relation to the sale of Uteron Pharma to Watson Pharmaceuticals for up to $305 million. Uteron is a Belgian based pharmaceuticals company developing a number of innovative women’s healthcare pharmaceuticals and medical devices. Watson paid an initial cash price of $150 million and agreed to pay up to a further $155 million based on future milestone achievement.

The transaction was governed by English law. Lawford Davies Denoon provided specialist Life Sciences advice and worked alongside corporate firms Nauta Dutilh in Belgium and Paris Smith in the UK. Jefferies provided financial advice to Uteron. SJ Berwin advised Watson.

31. January 2013: Alex Denoon presenting at Regulation of Stem Cell Therapies Conference in Paris on 31 January 2013

Alex gave a presentation on the Regulation of stem cell therapies at the IMCAS 15th Annual Congress in Paris on 31 January 2013. Alex spoke about when an autologous grafts of stem cell enriched adipose tissue becomes an unauthorised medicinal product.

1. December 2012: Alex Denoon presenting at Revising Medical Devices Regulation - The Legal Challenges Conference on 29 January 2013

Alex Denoon gave a presentation at the 'Revising Medical Devices Regulation - The Legal Challenges' Conference on 29 January 2013 in Tilburg.  Alex spoke about the dramatic impact of the proposed amendments to the EU laws regarding medical devices, IVDs and data protection. Full details of the conference can be found here.

13. November 2012: Seminar on Legal Issues in Synthetic Biology by Julian Hitchcock on 7 December 2012

Julian Hitchcock will be presenting our next Brown Bag Lunch Seminar entitled 'Legal Issues in Synthetic Biology' on 7 December 2012.

The seminar will all take place from 1pm to 2pm at our offices - 14A Clerkenwell Green, London, EC1R 0DP.

Attendance is free, but places are extremely limited. If you are interested in attending please email Katie Rouse.  

1. November 2012: Alex Denoon to give evidence to the House of Lords Science and Technology Select Committee on 27 November 2012

Alex will be giving evidence to the House of Lords Science and Technology Select Committee on 27 November 2012. This is part of the ongoing Inquiry into regenerative medicine. The Inquiry will make recommendations to Government on aspects of commercialisation, regulation and clinical development.

12. October 2012: Julian Hitchcock will be speaking at the European Parliament on 15 November 2012

Julian will be speaking at the European Parliament on 15 November 2012 with the former EU Commissioner for research, Philippe Busquin and one of Europe's most prominent stem cell scientists. The occasion is a public hearing organised by the European Humanist Federation, that aims to set out the case for continued EU funding of research using cells that have been derived, ultimately, from in vitro fertilised human eggs.

1. October 2012: Julian Hitchcock to attend a Joint Workshop on the Regulation of UK Regenerative Medicine on 30 October 2012

Julian is attending a Joint Workshop on the Regulation of UK Regenerative Medicine at the Medicines and Healthcare products Regulatory Agency (MHRA) on 30 October 2012. The workshop is organised by the MHRA, the Academy of Medical Sciences, Association of the British Pharmaceutical Industry, the Economic and Social Research Council and the Medical Research Council.

21. September 2012: Lawford Davies Denoon recommended by Legal 500 in Pharmaceuticals and Biotechnology

Lawford Davies Denoon is delighted to be recognised as ‘a very successful niche practice effectively cornering the UK IVF, regenerative therapies and medical device markets’ in the latest (2012) edition of the Legal 500. Alex Denoon is described as always having ‘creative ideas to deal with difficult issues, and is ideal for strategic boardroom counselling’. Please see here for the full review.

12. September 2012: Alex Denoon presenting at Cell Therapy Clinical Development Conference in Washington on 10 September 2012

Alex Denoon gave a presentation on 'Regulation of Cell Therapies in Europe' at the Cell Therapy Clinical Development Conference held in Arlington, USA on 10 - 11 September 2012.

While in Washington, Alex met with Congressmen on Capitol Hill and an industry body to discuss regulatory approval of stem cell therapies by the FDA and to compare the position in Europe.

12. September 2012: Julian Hitchcock to speak at the Westminster Business Forum and Westminster Health Forum Keynote Seminar

Julian will be speaking at the Westminster Business Forum and Westminster Health Forum Keynote Seminar in London on 25 October 2012, which will be addressing ‘The ‘Strategy for UK Life Sciences’ one year on – challenges for innovation and growth in biomedical and healthcare science’. The event will be chaired by the Rt Hon Paul Goggins MP and Dr Julian Huppert, MP.

12. September 2012: Julian Hitchcock to speak at the Franco-British Symposium on 16 October 2012

Julian will be speaking about emerging issues in advanced healthcare law at the Franco-British Symposium on Clinical Research to be held at the Royal Society on 16 and 17 October 2012. Julian will also be chairing the concluding session on the methodology and management of orphan diseases, innovative biotherapies in inflammatory and auto-immune diseases and therapeutic innovation for Alzheimer's disease.

12. September 2012: Julian Hitchcock to join the Science Business roundtable meeting of thought leaders in Brussels on 18 October 2012

Julian will be joining the Science Business roundtable meeting of thought leaders in Brussels on 18 October 2012. The aim of the meeting is "to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe" in the light of the recent ruling of the Court of Justice of the European Union in Brüstle v Greenpeace and the imminent debate in the European Parliament over EU funding of research involving cells originating from fertilised human eggs under the Horizon 2020 funding programme.

12. September 2012: Julian Hitchcock will be speaking at the European Parliament on 15 November 2012

Julian will be speaking at the European Parliament on 15 November 2012 with the former EU Commissioner for research, Philippe Busquin and one of Europe's most prominent stem cell scientists. The occasion is a public hearing organised by the European Humanist Federation, that aims to set out the case for continued EU funding of research using cells that have been derived, ultimately, from in vitro fertilised human eggs.

21. June 2012: Julian Hitchcock confirmed as a member of the Emerging Science and Bioethics Advisory Committee (ESBAC)

We are very pleased to announce that Julian Hitchcock of Lawford Davies Denoon has been confirmed as a member of the newly established Emerging Science and Bioethics Advisory Committee (ESBAC).

ESBAC is the main UK advisory body on the wider implications of developments in bioscience and its impact for health. The Committee is sponsored by the Chief Scientific Advisor for the Department of Health, England and aims to provide advice to UK Health Departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. The Committee also provides a forum to consider and develop coordinated advice across the wider science, health and academic communities to help set priorities in response to new developments.

The Committee provides expertise in health related biosciences and biotechnology, medicine as well as social, ethical, legal, commercial and public communication issues. Members hold office for up to three years and are not remunerated.

 

1. May 2012: Alex Denoon will be speaking at the EU Pharmaceutical Law Forum 2012 in Brussels on 22 May 2012

Alex Denoon will be giving a presentation on 'Clinical trials and investigations (non-implanted medical devices)' at the EU Pharmaceutical Law Forum 2012 in Brussels on 22 May 2012.  

26. April 2012: Alex Denoon presenting at Clinical Evaluations and Investigations for Medical Devices Conference in Dublin

Alex gave a presentation on the Impact of the proposed Data Protection Regulation on clinical investigations and data presentation at the Clinical Evaluations and Investigations for Medical Devices Conference in Dublin on 24 April 2013. Alex spoke about various recent developments at the EU level (proposed new Regulations and the EMA’s approach to disclosure of clinical trial data) and the impact on clinical investigations in Europe.

1. April 2012: Alex Denoon will be presenting a Masterclass on the Bribery Act in the Life Sciences Sector on 2 April 2012

Alex Denoon will be presenting a Masterclass on the Bribery Act in the Life Sciences Sector, with country specific commentary from Mathias Klümper re: Germany and Erik Vollebregt re: The Netherlands, at the SMi 'A Practical Guide to Implementing the Bribery Act in the Life Sciences Sector' Conference in London on 2 April 2012.

26. March 2012: Alex attends Commission Workshop on "Stem Cell Research and Patenting" in Brussels on 19 March 2012

Alex attends Commission Workshop on "Stem Cell Research and Patenting" in Brussels on 19 March 2012. 

1. January 2012: Alex Denoon will be speaking at the 28th Annual Congress of DGPharMed on 8-9 March in Köln

Alex Denoon will be speaking on the protection of Intellectual Property in the context of clinical trials at the 28th Annual Congress of DGPharMed (the German Pharmaceutical Association) on 8-9 March 2012 in Köln.  Full details of the event can be found here.

1. January 2012: Alex Denoon will be speaking at the Cell Society’s 2nd Annual Clinical Meeting in San Diego on 17-18 February 2012

Alex Denoon will be speaking on the regulation of cell-based therapies at the Cell Society’s 2nd Annual Clinical Meeting on 17-18 February 2012 in San Diego.  Full details of the event can be found here.

1. January 2012: Alex Denoon will be speaking at the 28th Annual Congress of DGPharMed on 8-9 March in Köln

Alex Denoon will be speaking on the protection of Intellectual Property in the context of clinical trials at the 28th Annual Congress of DGPharMed (the German Pharmaceutical Association) on 8-9 March 2012 in Köln.  Full details of the event can be found here.

20. December 2011: Alex Denoon to speak at a meeting at the Wellcome Trust: Embryonic Stem Cell Research: Beyond ‘Brüstle v Greenpeace’ on 21 December 2011

Alex will be giving a presentation on ‘Practical Ramifications of Brüstle v Greenpeace?’ at the Embryonic Stem Cell Research: Beyond ‘Brüstle v Greenpeace’ Meeting on 21 December 2011 at the Wellcome Trust, London.

2. December 2011: LDD article on Brüstle decision published in Cell Stem Cell

An article on the implications and consequences of the decision of the Court of Justice of the European Union in the case of Brüstle v. Greenpeace is today available in the journal Cell Stem Cell. The full text of the article is available here.

1. November 2011: Alex Denoon to speak at the Informa Life Sciences’ Cell Therapy Manufacturing Conference in Brussels: 30 November to 1 December 2011

Alex will be giving a presentation on 'How are cell therapies protected under IP and regulatory frameworks?' along with Anton Hutter of Venner Shipley and Dr Christopher Bravery of Consulting on Advanced Biologicals at the Informa Life Sciences’ Cell Therapy Manufacturing Conference in Brussels on 30 November 2011.

21. October 2011: Radio Interview re Brüstle v Greenpeace

Alex Denoon was interviewed by Material World (the leading radio science programme) on BBC Radio on 20 October with a representative from Greenpeace Germany. They discussed the decision of the Court of Justice of the European Union on the patentability of embryonic stem cells. The interview can he found here.

21. October 2011: Lawford Davies Denoon quoted in recent news articles regarding Brüstle v Greenpeace

The Guardian: European Court outlaws patents on embryonic stem cell techniques (here)

The Times: Europe’s ban on stem-cell patents threat to UK medicine industry (here)

Scrip Intelligence: Panic! No, don't panic! ECJ embryonic stem cells ruling divides opinion (here)

Nature: European court bans patents based on embryonic stem cells (here)

BioNews: European Court bars embryonic stem cell patents (here)

Economist: European science stemmed (here)

22. September 2011: Lawford Davies Denoon recommended by Legal 500 in Pharmaceuticals and Biotechnology

Lawford Davies Denoon is delighted to be recognised for its “impressively high-quality work and good understanding of the industry” in the latest (2011) edition of the Legal 500 (Legal 500).

Alex Denoon is described as ‘extremely good at providing to-the-point advice’.

20. September 2011: Alex Denoon appointed as a Trustee at Science Media Centre (“SMC”)

We are very pleased to announce that Alex has been appointed as a Trustee at the Science Media Centre (“SMC”). The SMC is an independent venture working to promote the voices, stories and views of the scientific community to the national news media when science is in the headlines. We are honoured to be asked to assist an organisation with as enviable a reputation as SMC.

24. August 2011: Alex Denoon co-authors editorial ‘The Ramifications of the Advocate General's Opinion in the Oliver Brüstle Case'

Alex Denoon and Mark Paton (from Fasken Martineau LLP) co-authored an editorial entitled ‘The Ramifications of the Advocate General's Opinion in the Oliver Brüstle Case’ which is scheduled to appear in Issue 9 of the EIPR (European Intellectual Property Review). 

24. August 2011: Alex Denoon co-authors editorial ‘Hard Cell'

Alex Denoon and Mark Paton (from Fasken Martineau LLP) co-authored an editorial entitled ‘Hard Cell’ which appeared in the May 2011 edition of the European Lawyer. The editorial addressed whether the recent opinion from the EU's Court of Justice could throw stem cell patents into turmoil.

11. May 2011: Alex Denoon to speak at the Informa Life Sciences’ 20th Annual EU Pharmaceutical Law Forum in Brussels: 17 – 18 May 2011

Alex will be giving a presentation on 'PMS, Risk Management Plans' along with Erik Vollebregt of Greenberg Traurig at the Informa Life Sciences’ 20th Annual EU Pharmaceutical Law Forum in Brussels on 18 May 2011. Full details of the event can be found here.

17. March 2011: Alex Denoon co-authors editorial ‘Multi-jurisdictional advertising of medical devices’

Alex Denoon, Erik Vollebregt (from Greenberg Traurig LLP in the Netherlands) and Mathias Klümper (from Lützeler und Partner Rechtsanwälte) co-authored an editorial entitled ‘Multi-jurisdictional advertising of medical devices – the legal framework in Germany, the Netherlands and the UK’. The full article can be found here.

This article originally appeared in the March-April issue of Regulatory Affairs Medtech (www.regulatoryaffairsmedtech.com).

23. February 2011: Alex Denoon will be speaking at the Royal Society of Medicine on 24 February 2011

Alex Denoon will be speaking at the Royal Society of Medicine on the pending decision regarding the Patentability of Embryonic Stem Cells in Europe and specifically the pending ECJ case of Brüstle v Greenpeace. The meeting (entitled The Europeanisation Of Health Care) is organised by the Open Section in association with the European Association of Health Law and the Institute of Advanced Legal Studies, University of London.

6. November 2010: Alex Denoon led a workshop at the Biobanking & Biorepositories Conference in Munich (27-28 October)

Alex gave a presentation entitled ‘Legally, what is a biobank?’ with Mathias Klümper of Lützeler und Partner Rechtsanwälte at the Biobanking & Biorepositories Conference held in Munich on 27–28 October. Alex and Mathias also led an interactive post-conference workshop on 29 October entitled ‘Obtaining Informed Consent in Different European Countries’.

29. September 2010: Alex Denoon co-authors editorial Can Regenerative Medicine Save Big Pharma's Business Model from the Patent Cliff?

The latest issue of the influential journal Regenerative Medicine (www.futuremedicine.com) includes an editorial written by Alex Denoon and Erik Vollebregt (from Greenberg Traurig LLP in the Netherlands). The editorial addresses the challenges facing the pharmaceutical industry and the role that regenerative medicine may play in assisting with those challenges.

17. August 2010: LDD is delighted to welcome Caroline Bruley

We are very pleased to welcome Caroline Bruley for five weeks at LDD as a trainee. Caroline is a French trainee lawyer working in Paris for the law firm Beslay + Le Calve (www.beslay-lecalve.com), which is also dedicated to the Life Sciences sector.  Caroline holds a Master's degree in General Private Law (Rennes I) and a Master's degree in Health Law (Paris XII – Sceaux).  Before completing her Bar Exam in September, Caroline is working here in order to gain experience in UK legislation and investigate how specific Life Science issues are regulated in the UK.  Caroline is working on a number of activities for our firm, with a special focus on IVF and stem cells.

15. June 2010: Alex Denoon to speak at a meeting of the Licensing Executive Society, Benelux in Rotterdam on 22 June 2010

Alex Denoon is speaking at a meeting of the Licensing Executive Society, Benelux in Rotterdam on 22 June 2010. Alex has been invited to present about intellectual property issues regarding stem cells.

1. June 2010: New Article in Regulatory Affairs Journal

An article regarding Post Marketing Surveillance is published in the Regulatory Affairs Journal - Devices. Alex Denoon and Erik Vollebregt co-authored an article entitled Meeting New PMS and Vigilance Requirements in the EU. The article was published in the May/June edition of the Journal.

26. February 2010: Alex Denoon to speak at the Medical Device Law and Compliance Forum in Brussels on 6-7 May 2010

Alex will be chairing the first day and giving a lecture at the Medical Device Law  and Compliance Forum in Brussels on 6-7 May 2010.  His lecture will update the current position as regards the regulation of Advanced Therapy Medicinal Products.  The event includes representatives from Cordis, Johnson & Johnson, Philips Healthcare, Siemens Healthcare, the Sorin Group, Stratpharma and Smiths Medical International. Details of the conference can be obtained here.

11. January 2010: Alex Denoon to lead workshop at the Medical Device PMS and Vigilance Annual Conference in Berlin

Alex will be leading a pre-conference workshop with Erik Vollebregt of Greenberg Traurig LLP entitled "The Interplay between Legal and Regulatory Challenges of PMS and Vigilance" on 15 February 2010 at the Informa Life Sciences 'Medical Device Post Market Surveillance and Vigilance' 5th Annual Conference in Berlin.  Delegates will also gain practical insights and experiences from leading figures in the medical device field including Johnson & Johnson, Boston Scientific, and others.  Details may be found here.